High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions.
PD-1/PD-L1
cervical cancer
high-risk HPV
immunotherapy
oncoproteins
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
02
2020
accepted:
11
05
2020
entrez:
23
7
2020
pubmed:
23
7
2020
medline:
23
7
2020
Statut:
epublish
Résumé
Cervical cancer is the fourth most common malignancy in women worldwide and a leading cause of cancer-related mortality in developing countries. Important etiological factors in this cancer are high-risk human papillomaviruses (HPV), as roughly 96% of cervical cancer cases are positive for these oncoviruses. On the other hand, it has been recently pointed out that E6/E7 oncoproteins of high-risk HPV can upregulate the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) axis. Likewise, several recent reports showed that checkpoint blockades targeting PD-1/PD-L1 pathways have achieved efficient clinical responses via suppressing cancer progression and improving survival in several types of human cancers including metastatic cervical cancer. In this review, we summarize recent advances in our understanding of the PD-1/PD-L1 signaling pathway and its interaction with high-risk HPV and their oncoproteins, which could have an important impact on the management of HPV-associated cancers including cervical.
Identifiants
pubmed: 32695664
doi: 10.3389/fonc.2020.00914
pmc: PMC7338567
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
914Informations de copyright
Copyright © 2020 Allouch, Malki, Allouch, Gupta, Vranic and Al Moustafa.
Références
Anticancer Res. 2013 Jun;33(6):2561-7
pubmed: 23749909
Carcinogenesis. 2010 Mar;31(3):402-10
pubmed: 20015862
J Immunol Res. 2019 Nov 4;2019:1919082
pubmed: 31781673
J Clin Oncol. 2017 Dec 20;35(36):4035-4041
pubmed: 29095678
Oncotarget. 2017 Dec 14;9(5):6015-6027
pubmed: 29464051
Front Oncol. 2019 Aug 02;9:682
pubmed: 31428574
Oncotarget. 2017 Jan 10;8(2):2171-2186
pubmed: 27974689
Sci Rep. 2015 Jan 07;5:7653
pubmed: 25563170
Immunology. 2013 Aug;139(4):513-22
pubmed: 23521696
Adv Exp Med Biol. 2013;774:77-101
pubmed: 23377969
Mod Pathol. 2017 Apr;30(4):577-586
pubmed: 28059093
J Cell Mol Med. 2019 Apr;23(4):2656-2666
pubmed: 30697971
J Virol. 2011 Aug;85(16):8208-16
pubmed: 21680517
Expert Rev Mol Diagn. 2017 Jul;17(7):711-722
pubmed: 28597695
J Immunother Cancer. 2019 Nov 26;7(1):323
pubmed: 31771649
Mod Pathol. 2015 Dec;28(12):1594-602
pubmed: 26403783
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Int J Gynecol Cancer. 2010 May;20(4):597-604
pubmed: 20442590
FEBS Lett. 2008 Apr 30;582(10):1564-8
pubmed: 18406353
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2014-24
pubmed: 16609010
Int J Mol Sci. 2018 Jun 08;19(6):
pubmed: 29890655
Immunol Rev. 2009 May;229(1):114-25
pubmed: 19426218
Cancer Manag Res. 2018 Jan 18;10:105-113
pubmed: 29403308
Semin Cancer Biol. 1999 Dec;9(6):405-11
pubmed: 10712887
Cancer Gene Ther. 2020 Apr;27(3-4):168-178
pubmed: 31455836
PLoS One. 2016 Nov 18;11(11):e0166266
pubmed: 27861596
Cancer Microenviron. 2011 Dec;4(3):361-75
pubmed: 21626415
Anticancer Res. 2017 Aug;37(8):4353-4360
pubmed: 28739728
Biochem Biophys Res Commun. 2017 Sep 16;491(2):493-499
pubmed: 28684311
Nat Rev Cancer. 2012 Sep;12(9):613-26
pubmed: 22898542
Tumour Biol. 2014 Jun;35(6):5083-93
pubmed: 24554414
Front Immunol. 2017 Jun 16;8:689
pubmed: 28670312
Genes Dev. 2009 Sep 15;23(18):2140-51
pubmed: 19759262
Onco Targets Ther. 2016 Aug 12;9:5023-39
pubmed: 27574444
Cancer Manag Res. 2019 May 15;11:4297-4312
pubmed: 31190995
Cell Signal. 2015 Mar;27(3):443-52
pubmed: 25499621
BMC Cancer. 2020 Jan 28;20(1):58
pubmed: 31992245
Mol Cancer. 2015 Apr 17;14:87
pubmed: 26022660
Cancer Cell Int. 2019 May 23;19:146
pubmed: 31143091
Onco Targets Ther. 2019 Nov 25;12:10099-10105
pubmed: 31819504
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Cell. 1992 Jun 26;69(7):1237-45
pubmed: 1535557
Lancet Oncol. 2009 Apr;10(4):321-2
pubmed: 19350698
J Immunother Cancer. 2019 Feb 12;7(1):43
pubmed: 30755279
Cell. 1993 Dec 3;75(5):843-54
pubmed: 8252621
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13421-6
pubmed: 18755897
Nat Med. 2003 May;9(5):562-7
pubmed: 12704383
Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7
pubmed: 17875987
Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25
pubmed: 16949997
Front Med. 2019 Aug;13(4):438-450
pubmed: 30826965
J Virol. 1989 Oct;63(10):4417-21
pubmed: 2476573
Int J Oncol. 2016 Oct;49(4):1737-45
pubmed: 27509846
Mediators Inflamm. 2016;2016:6891482
pubmed: 27721577
Diagn Pathol. 2017 Jun 17;12(1):45
pubmed: 28623908
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
J Natl Cancer Inst. 2015 Nov 17;108(1):
pubmed: 26577528
Oncogene. 2008 Feb 14;27(8):1071-8
pubmed: 17704805
JAMA Oncol. 2019 Jan 1;5(1):67-73
pubmed: 30267032
Cell. 1990 Dec 21;63(6):1129-36
pubmed: 2175676
J Thorac Oncol. 2015 Jun;10(6):910-23
pubmed: 25658629
RNA. 2009 Apr;15(4):637-47
pubmed: 19258450
Mol Med Rep. 2017 Mar;15(3):1063-1070
pubmed: 28075442
Cell Mol Life Sci. 2006 Apr;63(7-8):930-8
pubmed: 16596339
J Clin Oncol. 2019 Jun 10;37(17):1470-1478
pubmed: 30943124
Virology. 2009 Feb 20;384(2):335-44
pubmed: 19007963
Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4223-E4232
pubmed: 28484017
Biomed Res Int. 2015;2015:304584
pubmed: 26180794
Oncogene. 1992 Jan;7(1):27-32
pubmed: 1311063
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Nat Rev Drug Discov. 2015 Aug;14(8):561-84
pubmed: 26228759
Expert Opin Biol Ther. 2019 Sep;19(9):871-877
pubmed: 31322926
Microorganisms. 2019 Jul 13;7(7):
pubmed: 31337018
Oncol Lett. 2019 Jun;17(6):5193-5200
pubmed: 31186735
Front Pharmacol. 2019 Feb 01;10:65
pubmed: 30774597
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
J Virol. 1992 Dec;66(12):6893-902
pubmed: 1331501
Nat Immunol. 2009 Nov;10(11):1185-92
pubmed: 19783989
PLoS Pathog. 2013;9(5):e1003384
pubmed: 23717208
J Thorac Oncol. 2018 Nov;13(11):e227-e230
pubmed: 30368415
J Cancer. 2018 Jul 30;9(16):2938-2945
pubmed: 30123362
Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):623-631
pubmed: 29461619
Clin Infect Dis. 2017 May 1;64(9):1228-1235
pubmed: 28199532
Oncogene. 1999 Nov 18;18(48):6714-8
pubmed: 10597278
Gynecol Oncol. 2018 Mar;148(3):609-621
pubmed: 29666026
J Virol. 2001 Jun;75(12):5559-66
pubmed: 11356963
Curr Opin Obstet Gynecol. 2020 Feb;32(1):1-8
pubmed: 31833942
Hum Vaccin Immunother. 2014;10(7):1812-21
pubmed: 25424787
Nat Immunol. 2007 Mar;8(3):239-45
pubmed: 17304234
Virology. 2012 Mar 30;425(1):53-60
pubmed: 22284893
PLoS Pathog. 2019 Apr 19;15(4):e1007575
pubmed: 31002735
EMBO Mol Med. 2015 Sep 28;7(11):1426-49
pubmed: 26417066
Mod Pathol. 2016 Jul;29(7):753-63
pubmed: 27056074
Curr Opin Pharmacol. 2015 Aug;23:32-8
pubmed: 26047524
FEBS J. 2012 Oct;279(19):3530-3537
pubmed: 22805590
Nat Rev Clin Oncol. 2017 Apr;14(4):203-220
pubmed: 27805626
J Obstet Gynaecol Res. 2017 Oct;43(10):1602-1612
pubmed: 28833798
Blood. 2018 Jan 4;131(1):68-83
pubmed: 29118007
Science. 1990 Apr 6;248(4951):76-9
pubmed: 2157286
J Thorac Oncol. 2017 Sep;12(9):1421-1433
pubmed: 28629895
Int J Mol Sci. 2017 Jan 12;18(1):
pubmed: 28085111